Skip to main content
Premium Trial:

Request an Annual Quote

A Negative for PSA Test

Premium

A panel of experts from the US Preventive Services Task Force has determined that routine testing for prostate-specific antigen to test for possible prostate cancer in men is "doing more harm than good," reports ScienceInsider's Eliot Marshall. There is no need to screen healthy men for PSA, USPSTF said, as the test is not reliable in determining cancer risk and can lead to detrimental side effects from over-treatment. "Based on trial data it has prevented few deaths — at best potentially 1 in 1,000 men screened," Marshall says. "Yet the task force finds that for every 1,000 men screened, the subsequent medical treatment leaves one with a blood clot, two with treatment-related heart attacks, and up to 40 with impotence or urinary incontinence." This changes the task force's previous recommendation, released in 2008, that equivocated over whether men younger than 75 could receive any benefit from PSA screening. "After studying recent clinical trials, however, the task force scrapped its hedged language and endorsed a clear negative," Marshall adds.

The American Urological Association released a statement saying it is "outraged" at the task force's recommendation. AUA President Sushil Lacy further called the recommendation "inappropriate and irresponsible," especially for at-risk populations like African-American men.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.